ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism
ERK1/2 are potential therapeutic targets for diabetic cardiomyopathy by modulating fatty acid metabolism in the heart.
Authors
- Megan Coble
- Ruijie Liu (ORCID: https://orcid.org/0000-0002-2468-0579)
- J. Cano (ORCID: https://orcid.org/0000-0003-4495-4394)
- Chloë De Roo (ORCID: https://orcid.org/0000-0002-6623-3283)
- Erin McLean (ORCID: https://orcid.org/0000-0002-6273-593X)
- Annabel Maag
Institutions
- Grand Valley State University (US)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-01-22
- DOI
- https://doi.org/10.31083/fbl26700
- Citations
- 4
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 5.55
Funders
- Grand Valley State University